Cited by 63Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

A novel mechanism for the regulation of amyloid precursor protein metabolism

Open access
Chen, Qi, Kimura, Hideo, Schubert, David·2002·The Journal of Cell Biology

Abstract

Modifier of cell adhesion protein (MOCA; previously called presenilin [PS] binding protein) is a DOCK180-related molecule, which interacts with PS1 and PS2, is localized to brain areas involved in Alzheimer's disease (AD) pathology, and is lost from the soluble fraction of sporadic Alzheimer's disease (AD) brains. Because PS1 has been associated with γ-secretase activity, MOCA may be involved in the regulation of β-amyloid precursor protein (APP) processing. Here we show that the expression of MOCA decreases both APP and amyloid β-peptide secretion and lowers the rate of cell-substratum adhesion. In contrast, MOCA does not lower the secretion of amyloid precursor-like protein (APLP) or several additional type 1 membrane proteins. The phenotypic changes caused by MOCA are due to an acceleration in the rate of intracellular APP degradation. The effect of MOCA expression on the secretion of APP and cellular adhesion is reversed by proteasome inhibitors, suggesting that MOCA directs nascent APP to proteasomes for destruction. It is concluded that MOCA plays a major role in APP metabolism and that the effect of MOCA on APP secretion and cell adhesion is a downstream consequence of MOCA-directed APP catabolism. This is a new mechanism by which the expression of APP is regulated.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1083/jcb.200110151

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In vitro experiments have shown that induced expression of DOCK3 results in attenuated Aβ secretion through regulation of APP degradation.

    “In vitro experiments have shown that induced expression of DOCK3 results in attenuated Aβ secretion through regulation of APP degradation (80, 81).”

    From RHO to the DOCK for GDP disembarking: Structural insights into the DOCK GTPase nucleotide exchange factors (2021) · cites this paper as [80]

    The Results section ('MOCA reduces APP and Aβ secretion'; page not provided) reports that MOCA-expressing B103 cells secreted considerably less Aβ. The Discussion (page not provided) attributes the reduction to accelerated intracellular APP degradation. Our copy calls the expressed protein MOCA but does not establish that it is DOCK3, so the claim’s identification of the protein is not verified by this source alone. (LLM, conf=0.80)

    Experimental — accuracy not yet measured
  • There is already evidence that DOCK4 could be involved with AD and DBP.

    “There is already evidence that DOCK4 could be involved with AD and DBP.”

    From Multi-trait association studies discover pleiotropic loci between Alzheimer’s disease and cardiometabolic traits (2021) · cites this paper as [49]

    The Introduction and Results discuss MOCA and its relationship to DOCK180, not DOCK4. The passages retrieved for “DOCK4 DBP” and “DOCK4 involvement Alzheimer disease bipolar disorder” provide no evidence about DOCK4 or DBP, so this copy does not establish the claimed involvement. (LLM, conf=0.76)

    Experimental — accuracy not yet measured
  • Previous genetic studies have shown that DOCK4 variants are associated with multiple neurological phenotypes.

    “Previous genetic studies have shown that DOCK4 variants are associated with multiple neurological phenotypes, and DOCK2, the other member of DOCK4’s protein subfamily, expression is increased in the microglia of patient’s with AD [49, 50].”

    From Multi-trait association studies discover pleiotropic loci between Alzheimer’s disease and cardiometabolic traits (2021) · cites this paper as [49]

    The Introduction discusses MOCA, its similarity to DOCK180, and presenilin mutations linked to familial Alzheimer’s disease; it does not report genetic studies of DOCK4 variants. Searches for DOCK4 variants and neurological phenotypes found no passage addressing the claimed association in our copy. (LLM, conf=0.76)

    Experimental — accuracy not yet measured
  • DOCK2 expression is increased in the microglia of patients with AD.

    “Previous genetic studies have shown that DOCK4 variants are associated with multiple neurological phenotypes, and DOCK2, the other member of DOCK4’s protein subfamily, expression is increased in the microglia of patient’s with AD [49, 50].”

    From Multi-trait association studies discover pleiotropic loci between Alzheimer’s disease and cardiometabolic traits (2021) · cites this paper as [49]

    The Introduction and Results discuss MOCA and DOCK180, while the Abstract describes MOCA in Alzheimer’s disease. Searches for DOCK2 expression and microglia in patients with Alzheimer’s disease found no passage addressing the claimed increase. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Chen, Q., Kimura, H., & Schubert, D.
Affiliations
  • Salk Institute for Biological Studies (US)
  • National Center of Neurology and Psychiatry (JP)
Corresponding author
Schubert, David
Venue
The Journal of Cell Biology
Published
2002-07-01
Volume
158
Issue
1
Pages
79-89
ISSN
  • 0021-9525 (ISSN-L)
  • 1540-8140
OpenAlex
W2014633008
Cited by
63
References
66
Citations by year
2025: 1 · 2023: 1 · 2022: 1 · 2021: 4 · 2020: 1 · 2019: 4 · 2018: 2 · 2017: 2 · 2016: 1 · 2015: 4 · 2014: 4 · 2013: 5 · 2012: 1
FWCI
3.00
Type
journal article
Language
en
Open access
Locations
  • The Journal of Cell Biology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
Funders
  • Alzheimer's Association
  • National Institutes of Health
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Montreal Cognitive Assessment, amyloid precursor protein, APP processing, proteasomal degradation, cell adhesion, presenilin, Alzheimer's disease, DOCK180, proteasome inhibitors
MeSH terms
Animals, Bacterial Proteins, Cell Adhesion, Cell Line, Cysteine Endopeptidases, Dose-Response Relationship, Drug, Enzyme-Linked Immunosorbent Assay, Gene Expression Regulation, Laminin, Microscopy, Fluorescence, Multienzyme Complexes, Neurons, Phenotype, Time Factors, Transfection, Tumor Cells, Cultured, Blotting, Northern, Blotting, Western, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Microscopy, Confocal, Reverse Transcriptase Polymerase Chain Reaction, Proteasome Endopeptidase Complex, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review